A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease (AD).
Phase of Trial: Phase II/III
Latest Information Update: 07 Dec 2017
At a glance
- Drugs CNP 520 (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Acronyms Generation S2
- Sponsors Novartis Pharmaceuticals
- 02 Nov 2017 According to an Amgen media release, Amgen and Novartis today announced an expanded collaboration with the Banner Alzheimers Institute (BAI) to initiate a new trial - the Alzheimers Prevention Initiative (API) Generation Study 2.
- 11 Aug 2017 Status changed from not yet recruiting to recruiting.
- 02 May 2017 New trial record